| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CMM8; OCA1A; OCAIA; SHEP3 |
| WB Predicted band size | 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TYR |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TYR(酪氨酸酶)抗体的参考文献示例(文献为虚拟构造，仅作格式参考)：
1. **文献名称**: "Monoclonal Antibodies Targeting Tyrosinase for Melanoma Immunodetection"
**作者**: Smith J, et al.
**摘要**: 该研究开发了一种高特异性抗TYR单克隆抗体，用于黑色素瘤的免疫组化检测。实验表明，该抗体在转移性黑色素瘤组织中表现出高敏感性和特异性，可作为临床病理诊断的潜在工具。
2. **文献名称**: "Autoantibodies Against Tyrosinase in Vitiligo Pathogenesis"
**作者**: Lee H, et al.
**摘要**: 通过ELISA和蛋白质印迹分析，研究发现白癜风患者血清中TYR自身抗体水平显著升高，提示TYR自身免疫反应可能在色素脱失机制中起关键作用，为靶向治疗提供了新方向。
3. **文献名称**: "TYR Antibody-Based Therapeutic Nanoparticles for Melanoma Treatment"
**作者**: Zhang R, et al.
**摘要**: 研究构建了负载化疗药物的TYR抗体偶联纳米颗粒，可特异性靶向黑色素瘤细胞。体内实验显示显著抑制肿瘤生长，且对正常组织毒性较低，展示了TYR抗体在靶向治疗中的应用潜力。
4. **文献名称**: "Comparative Analysis of TYR Antibody Performance in Immunohistochemistry"
**作者**: Garcia M, et al.
**摘要**: 对比了四种商用TYR抗体在不同组织样本中的染色效果，发现克隆TY99在福尔马林固定石蜡包埋组织中稳定性最佳，为病理诊断中抗体选择提供了实用指南。
---
**注**：以上文献为示例，实际研究中请通过PubMed、Web of Science或Google Scholar等平台检索真实文献。建议使用关键词“tyrosinase antibody melanoma”、“tyrosinase autoantibody vitiligo”等进行筛选。
TYR (Tyrosinase) antibodies are immunological tools targeting tyrosinase, a key enzyme in melanin synthesis. Found in melanocytes and melanoma cells, tyrosinase catalyzes tyrosine oxidation to produce melanin pigments, critical for skin, hair, and eye pigmentation. Its dysregulation is linked to pigmentary disorders (e.g., albinism, vitiligo) and melanoma progression. TYR antibodies are widely used in research to study melanocyte biology, tumorigenesis, and drug responses. Clinically, they serve as diagnostic markers for melanoma in immunohistochemistry (IHC) and ELISA, aiding in tumor identification and monitoring.
Monoclonal TYR antibodies offer high specificity for detecting tyrosinase in tissue samples, while polyclonal variants enhance sensitivity in diverse experimental settings. Therapeutic applications are emerging, including antibody-based therapies and CAR-T cells targeting tyrosinase-expressing melanoma. However, challenges persist, such as cross-reactivity with similar epitopes in normal tissues, potentially causing off-target effects.
Recent advances focus on engineering humanized antibodies to improve safety and efficacy. TYR antibodies also contribute to understanding autoimmune responses in vitiligo, where autoantibodies against tyrosinase may drive melanocyte destruction. Overall, TYR antibodies bridge basic research and clinical innovation, holding promise for both diagnostic precision and therapeutic breakthroughs in oncology and dermatology.
×
